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Abstract
Background:  Dysregulated Notch signalling is believed to play an important role in the
development and maintenance of T cell leukaemia. At a cellular level, Notch signalling promotes
proliferation and inhibits apoptosis of T cell acute lymphoblastic leukaemia (T-ALL) cells. In this
study we aimed to identify novel transcriptional targets of Notch signalling in the T-ALL cell line,
Jurkat.
Results: RNA was prepared from Jurkat cells retrovirally transduced with an empty vector (GFP-
alone) or vectors containing constitutively active forms of Notch (N1ΔE or N3ΔE), and used for
Affymetrix microarray analysis. A subset of genes found to be regulated by Notch was chosen for
real-time PCR validation and in some cases, validation at the protein level, using several Notch-
transduced T-ALL and non-T-ALL leukaemic cell lines. As expected, several known transcriptional
target of Notch, such as HES1 and Deltex, were found to be overexpressed in Notch-transduced
cells, however, many novel transcriptional targets of Notch signalling were identified using this
approach. These included the T cell costimulatory molecule CD28, the anti-apoptotic protein
GIMAP5, and inhibitor of DNA binding 1 (1D1).
Conclusion: The identification of such downstream Notch target genes provides insights into the
mechanisms of Notch function in T cell leukaemia, and may help identify novel therapeutic targets
in this disease.
Background
Recently, studies have shown that Notch signalling may
play a central role in the development of T cell lymphob-
lastic leukaemia (T-ALL). Since the identification of
human Notch1 as a gene involved with a
t(7;9)(q34;q34.3) chromosomal translocation in a subset
of patients with T-ALL [1], several studies have implicated
dysregulated Notch signalling in the aetiology and patho-
genesis of T-ALL: Mice transplanted with bone marrow
cells transduced with a constitutively active form of
Notch1 develop T cell neoplasms [2], while mice trans-
genic for constitutively active form of Notch3 [3] develop
thymic lymphomas. Moreover, Notch3 has been shown
to be highly expressed by T-ALL cells and reduced level of
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Notch signalling was found to correlate with disease
remission [4]. More recently, Weng et al. have identified
Notch1 gain-of-function mutations in 50% of patients
with T-ALL ([5]. These mutations were clustered in the
heterodimerisation (HD) and PEST domains of Notch1.
HD mutations are thought to enable ligand-independent
Notch cleavage and activation, while PEST domain muta-
tions are thought to prolong the half-life of active Notch1.
More recently, a new class of Notch1 juxtamembrane
expansion mutations have been described in T-ALL which
lead to aberrant activation of Notch1 [6]. Interestingly,
treatment of T-ALL cell lines with gamma secretase inhib-
itors (GSIs;) to block Notch activation, inhibited prolifer-
ation [7] leading to apoptosis [8], indicating that targeting
the Notch signalling pathway may be of therapeutic value
in T-ALL. The mechanism of Notch-mediated cell-cycle
progression has been shown to be via the direct transcrip-
tional activation of c-myc [9,10], as well as inhibition of
PTEN expression [11] and activation of the AKT/PI3K
pathway.
Notch signalling has also been shown to inhibit apoptosis
in developing thymocytes and in T-ALL cells through a
variety of mechanisms: At the protein level, Notch acti-
vates the NF-κB pathway [3,12], and activates the PKB/
AKT/mTOR pathway-mediated p53 inhibition [13].
While some downstream transcriptional targets of Notch
signalling have been identified (for instance the basic
helix-loop-helix proteins HES1 [14], HERP1&2 [15]), it is
likely that many gene targets of Notch signalling remain
to be determined.
Palemero et al. have used microarray analysis to identify
novel targets of Notch signalling by treating T-ALL cell
lines with GSIs [10]. The cell lines used contained gain-of-
function mutations in the Notch1 gene and have over-
active Notch signalling [5]. Genes knocked down by GSIs
were then further investigated as putative Notch targets,
leading to the identification of c-myc as a Notch target
gene. A similar approach has also been taken by Weng et
al. in a parallel microarray study which also identified c-
myc as a target of Notch signalling [9].
We have used an alternative approach by taking a T-ALL
cell line (Jurkat) and transducing this cell line with con-
structs which mimic the gain-of-function Notch1 mutants
("ΔE" constructs which are constitutively activated by
gamma secretase). Cells expressing such ectopic Notch
constructs were used for Affymetrix microarray analysis to
identify putative novel Notch target genes. Following this
initial identification, extensive validation of such targets
was performed in several T-ALL cell lines using both
ectopic Notch expression and Notch knock-down meth-
odologies.
This approach has resulted in the identification of several
novel targets of Notch signalling which may play a role in
the functional effects of Notch in T-ALL. The identification
of such targets may reveal mechanisms by which Notch
signalling promotes proliferation and inhibits apoptosis
and as such may identify novel targets for therapeutic
strategies in T-ALL.
Methods
Constructs and cells
N1ΔE (base pairs 5143–7671) and N3ΔE (base pairs
4942–7045) cDNAs were cloned into the bicistronic ret-
roviral vector, pMX-eGFP (a kind gift from T. Kitamura,
Tokyo, Japan). pMSCV-DN-MAML1, containing cDNA
coding for aa13–74 was a kind gift from J. Aster, Harvard,
USA). Retrovirus was produced using the Phoenix ampho-
tropic packaging cell line. Empty pMX or pMSCV vector
was used to make the control GFP-alone virus. Cell lines
used were Jurkat, CEM, MOLT4, Peer, HPB-ALL, SIL-ALL
(T-ALL), Raji (Burkitt's lymphoma), and TF-1 (erythroleu-
kaemia), all cultured in RPMI media containing 10% Fetal
Bovine Serum.
Primary CD3+ T cells were isolated from peripheral blood
mononuclear cells by flow cytometry and stimulated with
30 ng/ml soluble anti-CD3/anti-CD28 and 100 U/ml IL2
(R&D Systems, Abingdon, UK) in RPMI media containing
10% Fetal Bovine Serum for 72 hrs prior to retroviral
transduction.
Retroviral supernatants were used to transduce cells in ret-
ronectin-coated tissue culture plates (BioWhittaker, Wok-
ingham, UK). After 48 hrs, GFP+ cells were sorted by flow
cytometry and cultured in normal growth medium.
Affymetrix microarray analysis
GFP+ Jurkat cells transduced with pMX, N1ΔE or N3ΔE
were sorted by flow cytometry and total RNA isolated
using RNA B (ABgene, Epsom, UK). Four independent
transductions were performed to yield 4 sets of total RNA
for Affymetrix microarray analysis. RNA quality was
checked using the RNA 6000 Nano Assay, and analyzed
on an Agilent 2100 Bioanalyser (Agilent Technologies,
South Queensferry, UK). RNA was quantified using a
Nanodrop ultra-low-volume spectrophotometer (Nano-
drop Technologies, Ringmer, UK) and Affymetrix human
genome U133A microarrays were used according to the
manufacturers' instructions (Affymetrix Inc. High
Wycombe, UK). The microarray data has been submitted
in MIAME compliant format to Arrayexpress public data-
base (E-MEXP-1744). Microarray data was initially
checked for quality using dChip (V2005) software (http:/
/www.dchip.org, [16]). Background correction and quan-
tile normalization were performed using RMA in Biocon-
ductor [17] and differential expression between GFP-Molecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
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alone and Notch constructs were calculated using Cyber-T
[18]. Gene lists of differentially expressed genes were con-
trolled for false discovery rate (fdr) errors using the
method of QVALUE [19]. Following false discovery rate
correction no genes were found to be differentially
expressed to a statistically significant level so it was
decided to rank by fold change and study the most upreg-
ulated genes by qPCR.
RT-PCR analysis
Total RNA was isolated from GFP+ transduced cell lines or
cells treated with gamma secretase inhibitor (GSI IX; Cal-
biochem) and reverse transcribed to cDNA using the High
Capacity cDNA Archive kit (Applied Biosystems, War-
rington, UK). Triplicate real-time PCR reactions were per-
formed with PowerSYBR SybrGreen reagents (Applied
Biosystems). Fold change in gene expression was deter-
mined using the "2-ddCT" method using GAPDH as an
endogenous control and cDNA from GFP-alone-trans-
duced cells as a calibrator. Primer sequences are shown in
Additional file 1.
GSI washout assay
Jurkat cells were incubated with 10 uM GSI IX for 48 hrs
then cells were washed twice with growth media and
seeded in growth media in the presence or absence of 20
uM cycloheximide to inhibit protein synthesis. RNA was
isolated from cells at various time-points and cDNA used
for gene expression analysis.
ELISA
Cells were seeded at 2 × 105/ml in fresh media and after 4
days, cell supernatants were used for VEGF ELISAs (R&D
Systems) according to the manufacturers' instructions.
Western blotting
Protein extracts from T-ALL cells were used for Western
blotting with 1:100 anti-GIMAP5 (anti-IAN4L1 polyclo-
nal antibody; Proteintech, Chicago, USA), anti ID1
(Autogen Bioclear, Calne, UK) or anti b-actin (Sigma,
Poole, UK) followed by HRP-conjugated secondary anti-
bodies.
Luciferase assay
Luciferase assays were performed in HEK293 cells with the
reporter construct pGa981–6 [20]. Cells were transfected
with reporter contruct and Notch constructs using
Fugene6 (Roche, Burgess Hill, UK). After 48 hrs in the
presence of DMSO (control) or GSI IX, cells were lysed
and luciferase assays performed using standard protocols.
Results
Expression of Notch and Validation of Constructs
Since mutations in Notch1 and over-expression of Notch3
have been associated with the development of T-ALL, we
focused our attention on these two genes. Quantitative
real-time PCR for Notch homologue expression con-
firmed that Notch1 and Notch3 are the predominantly
expressed Notch genes in the Jurkat and CEM T-ALL cell
lines (see Additional file 2). In order to identify transcrip-
tional targets of Notch signalling in T-ALL cells, we con-
structed bicistronic eGFP retroviruses containing the "ΔE"
Notch1 or Notch3 cDNA. These constructs express mem-
brane-bound Notch which is constitutively activated by
gamma secretase and as such can be inhibited by GSIs. To
confirm the activity of these constructs, luciferase assays
were performed using a Notch reporter (RBPJ-κ-Luc) with
and without GSIs. As can be seen in Additional file 2, both
N1ΔE and N3ΔE activated the RBPJ-κ-Luc reporter and
this activity could be inhibited by GSIs. However, the
activities of Notch intracellular domain (NICD) con-
structs (which do not require gamma secretase-mediated
activation) were not inhibited by GSIs. As well as verifying
the activity of these constructs, this result also shows the
increased activity of Notch1 compared with Notch3, a
finding reported elsewhere [21,22].
Affymetrix analysis of Notch ΔE-transduced cells
GFP-alone, N1ΔE and N3ΔE retroviruses were used to
infect the T-ALL Jurkat cell line with a transduction effi-
ciency of approximately 30% and GFP+ cells were sorted
by flow cytometry at 48 hrs to generate a pure (> 95%)
population of transduced cells for gene expression analy-
sis. This relatively early time-point was used to identify
genes directly upregulated by Notch signalling rather
those associated with secondary effects of Notch-induced
differentiation. Total RNA was made from sorted cells and
used for Affymetrix analysis. This procedure was per-
formed in quadruplicate and the Affymetrix data was used
to generate mean fold changes in gene expression using
the GFP-alone-transduced cells as the calibrator sample.
Statistical analysis using false discovery rate correction
showed no genes differentially expressed. However,
known targets of Notch signalling such as HES1 [23],
Notch3 [24], HERP1 and HERP2 [15] were in the top 50
genes ranked by fold change. The 15 genes most upregu-
lated by Notch1 based on analysis of microarray data are
shown in figure 1. A high degree of overlap was found
with genes upregulated by Notch3 (see Additional file 3).
This led us to select the top 10 upregulated genes (as well
as CD28; a putative Notch target gene of interest to us) for
further analysis. Below we present the results of these val-
idation studies.
CD28 is a Target of Notch Signalling
CD28 was of interest to us because of its well characterised
role in T cell activation [25] and its ability to positively or
negatively regulate thymocyte apoptosis ((([26-30]. CD28
was found to be upregulated by both Notch1 and Notch3
in Jurkat cells based on Affymetrix data (figure 1) and weMolecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
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validated this finding by real-time PCR using transduced
Jurkat, CEM and Molt4 cells as described above (figure
2.A). We investigated Notch-induced CD28 upregulation
at the protein level by flow cytometry. Analysis of GFP-
alone- or Notch-transduced Jurkat cells showed a clear
upregulation of CD28 expression at the cell surface while
untranfected GFP negative cells in the same culture did
not show Notch-induced CD28 upregulation (figure 2.B).
This effect was seen more clearly in CEM cells where very
little basal CD28 expression was seen. The majority of
Notch1-transduced cells were CD28 positive, while
untransduced cells in the same culture remained negative.
Treatment of all T-ALL cell lines with GSIs resulted in a
downregulation of cell surface CD28 expression (figure
3.A), showing that endogenous Notch signalling contrib-
utes to CD28 expression. This was confirmed using a GSI-
washout experiment (figure 3.B) which showed that
Notch-induced CD28 upregulation is not affected by
cyclohexamide and so does not require de novo protein
synthesis. Finally, DN-MAML downregulated CD28
mRNA and cell surface expression (figure 3.C&3D), con-
firming the contribution of endogenous Notch to basal
CD28 expression and also showing that the transcrip-
tional activity of Notch is necessary for this effect.
Together, the upregulation of CD28 in the absence of de
novo protein synthesis and the requirement of the tran-
scriptional activity of Notch shows that CD28 is a direct
transcriptional target of Notch. This finding is in agree-
ment with a recent study by Margolin et al. which used
ChIP-on-chip to identify direct transcriptional targets of
Notch1 [31] and found that there was a high degree of sig-
nificance in the affinity of Notch1 for the CD28 promoter
(see Additional file 4).
Finally, we transduced primary peripheral blood CD3+ T
cells with GFP-alone, N1ΔE, or N1ΔE with GSIs, and then
cells were stained for cell surface CD28. As shown in fig-
ure 3.E, a small increase in CD28 expression in response
to Notch was observed in these cells, while GSI treatment
reduced CD28 expression to below that of untreated cells.
While these are preliminary findings, it is clear that Notch
regulates CD28 expression in both cell lines and in pri-
mary cells.
PCR Validation of Affymetrix Data using Ectopic Notch
In order to validate this microarray data we used cDNA
from N1ΔE and N3ΔE-transduced Jurkat cells. Real-time
PCR analysis using a panel of known Notch target genes
confirmed the presence of active Notch signalling in
Notch-transduced cells (figure 4.A). These genes were
HES1 [23], HERP1&2 [15], Deltex [32], Notch3 [24] and
c-Myc [10]. Although the level of gene upregulation var-
Affymetrix microarray array analysis of Notch1-transduced Jurkat cells Figure 1
Affymetrix microarray array analysis of Notch1-transduced Jurkat cells. Jurkat cells were transduced with GFP-
alone, N1ΔE, or N3ΔE retrovirus and after 48 hrs, GFP+ cells were isolated by flow cytometry and total RNA extracted for 
Affymetrix array analysis. Data presented represents mean of 4 independent experiments. Graphical representation of micro-
array data showing the 15 genes most upregulated by Notch1. * represents p < 0.05 vesus GFP-alone-transduced cells based 
on p-values from n = 4 experiments. Using false discovery rate analysis, none of these changes were significant.Molecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
Page 5 of 16
(page number not for citation purposes)
CD28 expression is upregulated by ectopic Notch signalling Figure 2
CD28 expression is upregulated by ectopic Notch signalling. (A) PCR analysis of CD28 expression in Jurkat, CEM and 
Molt4 cells transduced with GFP-alone, N1ΔE, or N3ΔE retrovirus. * represents p < 0.05 verus GFP-alone transduced cells. (B) 
Flow cytometric analysis cell surface CD28 expression using the cells described above. GFP expression is a marker of trans-
duction.Molecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
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CD28 expression is downregulated by inhibition of Notch signalling Figure 3
CD28 expression is downregulated by inhibition of Notch signalling. (A) T-ALL cell lines were treated with 10 uM 
GSI IX (or DMSO) for 24 hrs and cell surface CD28 expression analysed by flow cytometry. * represents p < 0.05 verus 
DMSO-treated cells. (B) GSI washout experiment as described in figure 2 and CD28 mRNA expression analysis in Jurkat cells. 
* represents p < 0.05 verus cells at the zero timepoint. ** represents p < 0.05 verus cyclohexamide- cells (C) Real-time PCR 
expression analysis of CD28 using cDNA from GFP- (untransduced) or GFP+ (transduced) Jurkat cells transduced with GFP-
alone or N1ΔE retrovirus. * represents p < 0.05 verus GFP-alone transduced cells. (D) Cell surface CD28 expression using the 
cells described above. (E) CD28 expression in primary CD3+ cells transduced with GFP-alone, N1ΔE, or N1ΔE+GSIs.Molecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
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PCR validation of Affymetrix microarray data Figure 4
PCR validation of Affymetrix microarray data. cDNA from GFP-alone, N1ΔE, or N3ΔE-transduced Jurkat cells was used 
for PCR for a panel of known Notch target genes (A) as well as 10 novel genes most upregulated by Notch1 (B) based on 
microarray data in figure 1. Data represents fold change in gene expression from GFP-alone-transduced cells.Molecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
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ied, there was a general pattern of upregulation of these
genes in Notch-transduced cells.
We then sought to validate the expression of the 10 novel
genes most up-regulated by Notch1: EGF-containing fibu-
lin-like extracellular matrix protein 1 (EFEMP1 or
fibilin3), chitinase 3-like 2 (CHI3L2), vascular endothe-
lial growth factor (VEGF), transferrin receptor (TFRC),
RAN binding protein 2 (RANBP2), C-type lectin, super-
family member 6 (CLECSF6), immune associated nucle-
otide 4 like 1 (IAN4L1 or GTPase, IMAP family member 5
(GIMAP5)), RAN binding protein 2-like 1 (RANBP2L1),
inhibitor of DNA binding 1 (ID1), and SnoRNAs of the
box H/ACA Quantitative accumulation (SHQ1). Real-
time PCR analysis of cDNA from N1ΔE and N3ΔE-trans-
duced Jurkat cells confirmed the upregulation of these
genes in response to Notch signalling (figure 4.B). We fur-
ther extensively validated this data using a panel of 6 T-
ALL and non-T-ALL cell lines transduced with GFP-alone,
N1ΔE or N3ΔE retrovirus. As shown in Additional file 5,
data from these lines are broadly consistent with data
from Jurkat cells. Overall, this PCR analysis of cells trans-
duced with ectopic Notch has validated the Affymetrix
data.
Expression of Notch Target Genes following Inhibition of 
Notch Signalling
To investigate the response dynamics of the Notch target
genes identified by Affymetrix microarray analysis, we
used a GSI washout assay to measure gene expression in
response to endogenous Notch signalling. This assay
involves incubating cells with GSI to allow Notch to accu-
mulate at the cell surface. Washing the cells then removes
gamma secretase inhibition and leads to active Notch sig-
nalling [9]. As shown in figure 5.A, mRNA expression
analysis of known Notch target genes confirmed the valid-
ity of this method by showing an increase in gene expres-
sion following the removal of gamma secretase
inhibition. In all cases, GSI treatment led to a significant
decrease in gene expression, although the inhibition of c-
Myc expression was not as striking as other known Notch
targets. As expected, expression of these known Notch tar-
get genes increased following GSI washout and in some
cases, expression increased above that of the untreated
cells. Some cells were also incubated in parallel with
cyclohexamide to inhibit protein synthesis and allow us
to determine if de novo protein synthesis is required for
gene expression. This in turn would indicate whether
these genes are direct or indirect Notch targets. As
expected, cyclohexamide did not prevent the increased
gene expression following GSI washout in known Notch
target genes (which have mostly been characterised as
direct transcriptional targets). On the contrary, there was
a general increase in gene expression in the presence of
cyclohexamide. One explanation for this could be that an
inhibitor of gene expression (such as HES1) provides neg-
ative feedback for Notch target genes in normal circum-
stances. This is supported by the finding that HES1
physically interacts with CSL to inhibit Notch/CSL-medi-
ated transcription [33]. Moreover, oscillations in HES1
expression have been found to be due to auto-inhibition
of HES1 transcription [34]. In the presence of cyclohexa-
mide, a reduction in the protein level of an inhibitor such
as HES1 may allow Notch to increase gene expression lev-
els without any negative feedback mechanism.
When novel Notch target genes were analysed (figure
5.B), we found a significant decrease in gene expression in
all cases following GSI treatment, although the degree of
reduction in gene expression for RANBP, RANBP2L1,
TFRC and CHI3L2 was small compared to known Notch
target genes. Of the other genes (EFEMP1, CLECSF6,
GIMAP5, VEGF, ID1 and SHQ1), all showed a significant
increase in gene expression 4 hrs following GSI washout,
and this was not affected by the presence of cyclohexam-
ide, indicating that de novo protein synthesis is not
required for the Notch-induced transcription of these
genes.
Inhibition of known and novel Notch target gene expres-
sion was also analysed by GSI treatment of a panel of 5 T-
ALL cell lines. Following treatment with GSIs (10 uM GSI
IX for 24 hrs), real-time PCR was used to measure reduc-
tion in target gene expression and the mean fold change
from these 5 T-ALL lines are shown in Additional file 6.
The data broadly correlates with those of the GSI washout
experiment.
Finally, we analysed gene expression in Jurkat cells trans-
duced with GFP-alone vector or a dominant-negative mas-
termind-1 (DN-MAML) construct. This construct inhibits
the transcriptional activity of Notch signalling and as can
be seen in figure 6, inhibits the transcription of known
Notch target genes. When novel Notch target genes were
analysed, 4 genes out of 10 (TFRC, RANBP2, RANBP2L1
and CLECSF6) were not downregulated in the presence of
DN-MAML.
Combining the data from figures 5B &6B, EFEMP1, VEGF,
GIMAP5, ID1 and SHQ1, are upregulated by GSI-washout
(without a requirement for de novo protein synthesis) and
require Notch transcriptional activity since DN-MAML
downregulates these genes, indicating that this set of
genes are novel direct transcriptional targets of Notch. In
support of this finding, Margolin et al. have recently per-
formed a ChIP-on-chip study using T-ALL cell lines to
identify direct transcriptional targets of Notch signalling.
We have analysed the data from this study, focussing on
the genes identified by us, and found that the genes whose
promoter regions show significant Notch1 bindingMolecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
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Identification of direct notch targets using a GSI washout experiment Figure 5
Identification of direct notch targets using a GSI washout experiment. Jurkat cells were treated with 10 uM GSI (or 
DMSO (untreated)) for 48 hours to accumulate cell surface Notch before washing to permit Notch signalling. After washing, 
cells were treated with 20 uM cyclohexamide (CHX) or ethanol (vehicle control) to inhibit protein synthesis. After 4 hrs, RNA 
was isolated and cDNA made for real-time PCR analysis of known Notch target genes (A) and novel Notch target genes (B). 
Expression values were calculated using cDNA from untreated cells as the calibrator sample. * represents p < 0.01 versus 
untreated cells (effect of Notch inhibition). ** prepresents p < 0.01 versus GSI-treated cells (effect of Notch signalling). *** rep-
resents p < 0.01 versus washout cells (effect of cyclohexamide treatment).Molecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
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(EFEMP1, VEGF, IAN4L1/GIMAP5, ID1, SHQ1 and
CD28; Additional file 4) are generally those which
respond significantly in the GSI washout experiment (fig-
ure 5.B).
Genes Downregulated by Notch
We also investigated genes downregulated by Notch sig-
nalling. It is likely that such genes are secondary targets of
Notch whose transcription is inhibited by bHLH repres-
sors such as HES1, HERP1&2 or ID1. However, real-time
PCR analysis of cDNA from T-ALL cells failed to validate
the majority of genes identified by microarray analysis as
downregulated by Notch. One exception was IGLL1
(CD179b; figure 7), where ectopic Notch down-regulates
IGLL1 expression, while GSI-treatment or DNMAML
expression increases IGLL1 expression in Jurkat cells.
However this effect was not consistently seen in other T-
ALL cell lines. Mutations in IGLL1 have been shown to
lead to B cell deficiencies in both mice and humans ([35])
and given the role of Notch in promoting T cell develop-
ment at the expense of B cell fate, it is possible that one
such mechanism could be the downregulation of IGLL1.
VEGF, ID1 and GIMAP5 are upregulated by Notch at the 
protein level
Of the novel Notch target genes so far analysed at the
mRNA level, we chose to focus on VEGF, ID1, and
GIMAP5 because of their known involvement in cancer or
T cell development.
Inhibition of Notch signalling using DN-MAML Figure 6
Inhibition of Notch signalling using DN-MAML. Jurkat cells were transduced with pMSCV (GFP-alone control vector) or 
DN-MAML and the gene expression levels of known Notch target genes (A) and novel Notch target genes (B) were analysed. 
* represents p < 0.01 versus the GFP-alone control cDNA sample.Molecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
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At the mRNA level, VEGF is expressed at low levels in GFP-
alone transfected Jurkat cells and is only upregulated by
ectopic Notch1 (not Notch3). To confirm this finding at
the protein level, we performed ELISAs on supernatants of
cells transduced with GFP-alone, N1ΔE and N3ΔE retrovi-
ruses. As can be seen in figure 8.A, virtually no basal
expression of VEGF protein is detected in supernatants
from GFP-alone or N3ΔE-transduced Jurkat cells, whereas
N1ΔE-transduced cells produce detectable levels of VEGF.
The lack of detectable basal levels of secreted VEGF pro-
tein is contrary to the gene expression data shown in fig-
ures 5 &6, where GSI treatment and expression of DN-
MAML decreased VEGF mRNA levels in Jurkat cells. This
lack of correlation between VEGF mRNA and secreted
VEGF protein levels could be due to a number of factors
including post-transcriptional regulation of VEGF expres-
sion or regulation of VEGF protein secretion in the cell
supernatants. This finding suggests that although ectopic
Notch1 may promote VEGF protein expression, Notch
does not necessarily contribute to basal VEGF protein
expression in T-ALL cells.
We next analysed CEM cells which express detectable lev-
els of secreted VEGF protein (figure 8.A). As with Jurkat
cells, ectopic expression of Notch1, but not Notch3 upreg-
ulated VEGF protein expression. However, transduction
with DN-MAML did not downregulate VEGF protein
expression. Overall, these findings confirm the upregula-
tion of VEGF by ectopic Notch1, however it is unlikely
that endogenous Notch regulates basal VEGF expression
in T-ALL cells.
ID1 expression was found to be upregulated by both
Notch1 and Notch3 (figure 4.A) and downregulated by
GSI-treatment and DN-MAML (figures 5 &6). Analysis of
gene expression in Jurkat cells following GSI washout
showed a rapid induction of ID1 transcription (within a
similar time-scale to that of HES1 and Deltex; figure 8.B).
GSI-dependent downregulation of ID1 protein expression
was confirmed by western blotting (figure 8.C), confirm-
ing that endogenous Notch signalling regulates ID1
expression.
GIMAP5 (IAN4L1) belongs to a family of signalling pro-
teins which are thought to regulate T cell development
and survival [36]. GIMAP5 has been shown to have anti-
apoptotic functions and has been shown to physically
interact with Bcl-2 [37,38]. As such it represents a good
candidate protein for mediating the anti-apoptotic func-
tions of Notch1. Induction of gene expression occurred
within 4 hrs of GSI-washout (figure 8.B), and regulation
by Notch at the protein level was confirmed by Western
blotting (figure 8.C). Furthermore, in a separate study we
have used siRNA-mediated knockdown of GIMAP5
expression to show that GIMAP5 mediates some of the
protective effect of Notch to glucocorticoid-induced apop-
tosis (manuscript submitted for publication).
Other members of the GIMAP family are not represented
on the Affymetrix array, so we sought to determine
whether these genes, like GIMAP5, are also regulated by
Notch. As shown in Additional file 7, a general upregula-
tion of all GIMAP family genes (GIMAP3 being a pseudo-
IGLL1 is downregulated by Notch signalling in Jurkat cells Figure 7
IGLL1 is downregulated by Notch signalling in Jurkat cells. (A) Affymetrix data from Notch-transduced Jurkat cells. (B) 
cDNA from GFP-alone, N1ΔE, or N3ΔE-transduced Jurkat cells was used for PCR analysis of IGLL1 expression (using GFP-
alone-treated cells as the calibrator). IGLL1 expression in response to GSI treatment was also analysed using DMSO (vehicle 
control)-treated cells as the calibrator. Expression of IGLL1 in DN-MAML-expressing cells was analysed using pMSCV (GFP-
alone vector)-transduced cells as the calibrator. * represents p < 0.05 vesus the relevant calibrator sample.Molecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
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Analysis of Notch-induced VEGF, ID1 and GIMAP5 expression Figure 8
Analysis of Notch-induced VEGF, ID1 and GIMAP5 expression. (A) Supernatants from GFP-alone, N1ΔE, or N3ΔE-
transduced Jurkat or CEM cells were used for VEGF ELISAs to analyse secreted VEGF protein levels in response to ectopic 
Notch. Supernatants of CEM cells transduced with DN-MAML were also analysed to show the contribution of endogenous 
Notch transcriptional activity on VEGF expression. * represents p < 0.05 versus GFP-alone-transduced cells (B) Jurkat cells 
were used for a GSI washout assay and ID1 and GIMAP5 gene expression analysed over 4 hrs following washout using cDNA 
from untreated cells as the calibrator sample. (C) Western blot analysis of ID1 and GIMAP5 expression using protein extracts 
from Jurkat cells treated with a dose range of GSI IX.Molecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
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gene) in response to either ectopic Notch1 or Notch3 is
seen in Jurkat cells. Furthermore, in a sample of primary
CD3+ preripheral blood cells, ectopic Notch1 generally
upregulated this family of genes, while GSI-treatment
reduced their expression levels (Additional file 7). These
data indicate that the GIMAP family of proteins may be
key mediators of Notch-induced regulation of T-cell
development.
Discussion
In this study we have used an approach utilising ectopic
expression of Notch to identify novel target genes in T-
ALL. Using this approach we have identified a set of novel
Notch target genes and we validated the Affymetrix micro-
array data by real-time PCR analysis of the top 10 novel
Notch1 target genes using a panel of cell lines transduced
with Notch constructs. Although we have found little
overlap between our set of Notch targets and those of
other studies where Notch target genes have been identi-
fied by GSI treatment [9,10,39,40], some genes have been
identified previously: SHQ1 [10], VEGF and ID1 [40].
This relative lack of overlap between our study and those
of others probably reflects the different approaches taken
by us (ectopic expression of Notch constructs) and others
(GSI-inhibition of endogenous Notch). It is possible that
Notch targets expressed at a low level endogenously may
be more clearly identified in a microarray following
ectopic Notch expression, whereas targets expressed at sat-
urating levels may not be further upregulated by ectopic
Notch (and not easily identified by microarray analysis)
but may be more readily identified by inhibition of
endogenous Notch activity. The level of Notch activity in
Jurkat cells (and other T-ALL cells used in this study) is
clearly not saturated since many known Notch target
genes are upregulated following ectopic Notch expression
(based on microarray and PCR analysis), suggesting that
this approach is a valid way of identifying novel targets of
Notch signalling. Furthermore, given the cell context-spe-
cificity of Notch target gene expression, it was important
for us to use a T-ALL cell line in our study which has aimed
to identify such relevant to T cell leukemia, even though
Jurkat cells already express an overactive form of Notch1.
It is possible that a combined approach of overexpression
and knockdown could reveal a more complete set of target
genes following microarray analysis.
To determine which of our set of putative Notch target
genes are regulated by endogenous Notch signals we used
GSI-mediated inhibition of Notch activation, and DN-
MAML-mediated inhibition of Notch transcriptional
activity. This strategy showed the majority of these genes
to be regulated by endogenous Notch activity.
Recently, Margolin et al. have performed a genome-wide
ChIP-on-chip study to identify direct transcriptional tar-
gets of Notch1 [31]. Probe binding affinities to Notch/
CSL/DNA complexes were ranked in order of p-values in
order to identify significant physical interactions between
Notch1 and gene promoters. Analysis of this data has con-
firmed that several of the genes identified by us are direct
targets of Notch signalling (EFEMP1, VEGF, ID1, SHQ1,
IAN4L1/GIMAP5, CD28).
Of the 10 genes most upregulated by Notch1, we found
four to be of particular interest: VEGF, ID1, IAN4L1
(GIMAP5), and CD28. At the protein level, VEGF was
shown to be upregulated by Notch1 (but not Notch3) in
Jurkat and CEM cells, although VEGF expression was not
downregulated by either GSI treatment or DN-MAML.
This finding was notable since with the exception of VEGF
transcriptional differences between Notch1 and Notch3
were limited to the extent of gene regulation, an unsur-
prising finding given that all Notch homologues mediate
transcription via CSL. The fact that ectopic Notch1 but not
ectopic Notch3 can upregulate VEGF expression may indi-
cate the presence of a mechanism whereby Notch1 may
interact with factors upstream of VEGF expression in a
gamma secretase-independent fashion. VEGF has previ-
ously been shown to be expressed by T-ALL cell lines
[41,42] and may contribute to angiogenesis in T cell lym-
phomas. As such, Notch-induced VEGF expression may
represent an important step in lymphoma development.
ID1 expression was also found to be induced by Notch
and the identification of this gene as a transcriptional tar-
get of Notch is not surprising given that ID1 belongs to the
same family of basic helix-loop-helix proteins as HES1
and HERP1&2 [43]. Two studies have shown have also
shown ID1 to be downstream of Notch signalling: Talora
et al. [44] have shown that Notch3 transgenic mice express
high ID1 levels, and that Notch induced ID1 expression is
mediated by pre-TCR-induced extracellular-signalling-reg-
ulated kinase 1/2. Secondly, Fox et al. [45] have shown an
increase in ID1 expression in human embryonic stem cells
transfected with Notch. Our data now shows that Notch
regulates ID1 expression in T-ALL cell lines.
GIMAP5 was found to be upregulated by Notch and,
whilst the exact role of GIMAP5 is unclear, it has been
shown to interact with Bcl-family members and play an
important role in inhibiting apoptosis during T cell devel-
opment [36]. Further studies will determine the role of
GIMAP5 in mediating the functional effects of Notch dur-
ing normal thymocyte development and in the develop-
ment of T cell leukaemia. We have investigated the
relationship between GIMAP5 upregulation and apopto-
sis in T-ALL cells (manuscript submitted for publication).Molecular Cancer 2009, 8:35 http://www.molecular-cancer.com/content/8/1/35
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Our finding that CD28 is a direct target of Notch signal-
ling is of interest both in terms of T cells development and
leukaemia, and also in mature T cell activation. The role
of CD28 in T cell development is unclear. CD28 stimula-
tion in developing thymocytes has been shown to be
important for regulatory T cell development [46], as has
Notch signalling [47], and it is therefore possible that
Notch-induced CD28 expression may mediate this devel-
opmental process. The role of CD28 in thymocyte apop-
tosis is unclear. CD28 activation can inhibit
glucocorticoid-mediated apoptosis ((([26,27,30], how-
ever other studies show a pro-apoptotic role of CD28
stimulation during negative selection (e.g. [28,29]) that is
determined by signal strength [48]. It is clear from our
experiments that although Notch signalling regulates
CD28 expression, CD28 expression is not solely depend-
ent on Notch signalling since neither GSI treatment, nor
DN-MAML, abolishes CD28 expression. It is likely that
Notch signalling plays a role in "fine-tuning" CD28
expression and thus helping to determine the fate of
developing thymocytes. Although we have shown that
Notch can regulate CD28 expression in peripheral blood
T cells, it remains to be seen whether Notch is able to reg-
ulate CD28 expression in primary thymocytes.
Conclusion
We have identified novel transcriptional targets of Notch
signalling in T cell leukaemia, and confirmed changes at
the protein level for several of these targets which have a
known role in cancer and T cell development. The identi-
fication of these genes will form the basis of further stud-
ies aimed at understanding the mechanism of Notch
induced changes in T-ALL cells.
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